Jan Baumbach and his team developed CoVex, the first online platform for SARS-CoV-2 and SARS-CoV-1 host interactome exploration and drug (target) identification. (Photo: Tom Schulte/ FOM)
Jan Baumbach and his team developed CoVex, the first online platform for SARS-CoV-2 and SARS-CoV-1 host interactome exploration and drug (target) identification. (Photo: Tom Schulte/ FOM) - Currently, the corona pandemic is dominating the entire social life in Germany and in many other parts of the world. We are working flat out in order to better help the more than one hundred thousand seriously ill people in hospitals. One promising approach to extending current treatment methods is to use existing and approved drugs to combat the virus. In order to find out which existing drugs might be suitable for the treatment of Covid-19, numerous research groups from all over the world are working on systems medicine approaches. A research team from the Chair of Experimental Bioinformatics (ExBio) at the TUM School of Life Sciences of the Technical University of Munich (TUM) has now developed the first online data analysis platform for this purpose. The so-called Coronavirus Explorer (CoVex) integrates the virus-human interactome for SARS-CoV-2 and SARS-CoV.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
